3[1]Standifer KM, Rossi GC, Pasternak GW. Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits [J]. Mol Pharmacol, 1996, 50(2):293 - 298.
4[2]Yoon SH, Lo TM, Loh HH, et al. Delta-opioid-induced liberation of Gβγ mobilizes Ca2+ stores in NG108-15 cells [J]. Mol Pharmacol, 1999, 56(5):902 - 908.
5[3]Sanchez-Blazquez P, Garzon J. Intracerebroventricular injection of antibodies directed against Gs α enhances the supraspinal antinociception induced by morphine, β-endor phin and clonidine in mice[J]. Life Sci, 1992, 51(24):PL237- PL242.
6[4]Sanchez- Blazquez P, Carcia-Espana A, Garzon J. In vivo injection of antisense oligodeoxynucleotides to Gα subunits and supraspinal analgesia evoked by μ and δ opioid agonists [J]. J Pharmacol Exp Ther, 1995, 275(3): 1590- 1596.
7[5]Lane-Ladd SB, Pineda J, Boundy VA, et al. CREB in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence [J]. J Neurosci,1997, 17(20) :7890 - 7901.
8[6]Tso PH, Yung LY, Wong YH. Regulation of adenylyl cyclase, ERK1/2, and CREB by Gz following acute and chronic activation of the δ-opioid receptor [J]. J Neurochem, 2000, 74(4): 1685 - 1693.
9[7]Lou L, Pei G. Modulation of protein kinase C and cAMPdependent protein kinase by δ-opioid[J]. Biochem Biophys Res Commun, 1997, 236(3) :626 - 629.
10[8]Buzas B, Rosenberger J, Cox BM. Regulation of δ-opioid receptor mRNA levels by receptor-mediated and direct activation of the adenylyl cyclase-protein kinase A pathway[J].J Neurochem, 1997, 68(2) :610 - 615.
1Early J, Whitten JS. Naltrexone/Buproprion ( Contrave ) for weight loss[ J]. Am Faro Physician,2015,91 (8) :554.
2Yanovski SZ, Yanovski JA. Nahrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity [ J ]. JAMA, 2015,313(12) :1213-1214.
3李君.安非他酮应用与精神分裂症病人戒烟的疗效分析[D].济南:山东大学.
4Greenway FL, Whitehouse M J, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity[ J]. Obesity,2009, 17( 1 ) :30-39.
5Orexigen Therapeutics Inc. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Nahrexone Sustained Release (SR) UsedinContrave(R). www. orexigen, corn,06 Oct 2008 Media Release.
6Fleming GA. Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, and Cardiometabolic Disorders [ M ]// Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. Springer London,2015:283-304.
7George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity [ J ]. J Cardiovasc Pharmacol Ther, 2014,19 (1) :65-76.
8Roh E, Kim MS. New and emerging drugs for the treatment of obesity[ J]. J Korean Med Assoc,2015,58(5 ) :452-457.
10Obesity;Orexigen (R) Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet. Report Information from ProQuest. 2015(5) :1-3.
